SG/CALL/ASTRAZENECA/9000/0.1/20.12.24 Stock

SG/CALL/ASTRAZENECA/9000/0.1/20.12.24 Share Price

DE000SU9A8Y8

Real-time Boerse Frankfurt Warrants 06:02:41 02/07/2024 pm IST
4.06 ^EUR	+0.50%

Current month	-0.49%
1 month	+1.76%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart SG/CALL/ASTRAZENECA/9000/0.1/20.12.24

Latest news about ASTRAZENECA PLC

Astrazeneca - Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advanced or recurrent endometrial cancer	06:47pm	AQ
Astrazeneca - Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention	06:47pm	AQ
ASTRAZENECA : Jefferies reaffirms its Neutral rating	05:10pm	ZD
Deutsche Bank cuts Quilter, ups Polar Capital	02:18pm	AN

More news

Quotes 5-day view

Date	Price	Change
02/24/02	4.06	+0.50%
01/24/01	4.04	-0.49%
28/24/28	4.06	-1.69%
27/24/27	4.13	-4.84%
26/24/26	4.34	+0.23%

Real-time Boerse Frankfurt Warrants

Last update July 02, 2024 at 06:02 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	Société Générale
WKN	SU9A8Y
ISIN	DE000SU9A8Y8
Date issued	14/02/2024
Strike	9,000 p
Maturity	20/12/2024 (171 Days)
Parity	10 : 1
Emission price	1.52 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	4.62 €
Lowest since issue	1.47 €
Delta	0.98x
Omega	3.492
Premium	1.84x
Gearing	3.55x
Moneyness	1.358
Difference Strike	-3,201 p
Difference Strike %	-35.57%
Spread	0.02 €
Spread %	0.49%
Theoretical value	4.070
Implied Volatility	23.41 %
Total Loss Probability	2.386 %
Intrinsic value	3.804
Present value	0.2664
Break even	12,447.69 €
Theta	-0.01x
Vega	0x
Rho	0.05x

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company